Article
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
American journal of hypertension - 1 Dec 2003
Bis Joshua C, Smith Nicholas L, Psaty Bruce M, Heckbert Susan R, Edwards Karen L, Lemaitre Rozenn N, Lumley Thomas, Rosendaal Frits R
Abstract excerpt
UNLABELLED: The ThrThr genotype of the angiotensinogen (AGT) Met235Thr polymorphism has been associated with elevated AGT levels, hypertension, increased heart disease risk, and improved blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitors. We hypothesized that risk of s...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.